Cipher Pharmaceuticals Stock Performance
| CPH Stock | CAD 13.32 0.29 2.13% |
The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cipher Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cipher Pharmaceuticals is expected to be smaller as well. Cipher Pharmaceuticals right now shows a risk of 2.64%. Please confirm Cipher Pharmaceuticals downside variance, daily balance of power, and the relationship between the maximum drawdown and skewness , to decide if Cipher Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cipher Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical indicators, Cipher Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 28.8 M |
Cipher |
Cipher Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,388 in Cipher Pharmaceuticals on November 8, 2024 and sell it today you would lose (27.00) from holding Cipher Pharmaceuticals or give up 1.95% of portfolio value over 90 days. Cipher Pharmaceuticals is generating 0.0021% of daily returns assuming 2.6374% volatility of returns over the 90 days investment horizon. Simply put, 23% of all stocks have less volatile historical return distribution than Cipher Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cipher Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cipher Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cipher Pharmaceuticals, and traders can use it to determine the average amount a Cipher Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 8.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CPH |
Estimated Market Risk
| 2.64 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cipher Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cipher Pharmaceuticals by adding Cipher Pharmaceuticals to a well-diversified portfolio.
Cipher Pharmaceuticals Fundamentals Growth
Cipher Stock prices reflect investors' perceptions of the future prospects and financial health of Cipher Pharmaceuticals, and Cipher Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cipher Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0506 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 393.04 M | ||||
| Shares Outstanding | 25.59 M | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 13.16 X | ||||
| Revenue | 21.16 M | ||||
| Gross Profit | 21.38 M | ||||
| EBITDA | 11.26 M | ||||
| Net Income | 20.38 M | ||||
| Cash And Equivalents | 9.25 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 353 K | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 3.86 X | ||||
| Cash Flow From Operations | 16 M | ||||
| Earnings Per Share | 0.91 X | ||||
| Market Capitalization | 348.27 M | ||||
| Total Asset | 86.03 M | ||||
| Retained Earnings | 66.27 M | ||||
| Working Capital | 43.02 M | ||||
About Cipher Pharmaceuticals Performance
By examining Cipher Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Cipher Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cipher Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 307.62 | 202.06 | |
| Return On Tangible Assets | 0.27 | 0.28 | |
| Return On Capital Employed | 0.14 | 0.13 | |
| Return On Assets | 0.21 | 0.22 | |
| Return On Equity | 0.23 | 0.24 |
Things to note about Cipher Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cipher Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cipher Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cipher Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| The company has C$353,000 in debt which may indicate that it relies heavily on debt financing | |
| About 42.0% of the company shares are held by company insiders |
- Analyzing Cipher Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cipher Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cipher Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cipher Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cipher Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cipher Pharmaceuticals' stock. These opinions can provide insight into Cipher Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.